<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295460</url>
  </required_header>
  <id_info>
    <org_study_id>FIS-TAR-01-2019</org_study_id>
    <nct_id>NCT04295460</nct_id>
  </id_info>
  <brief_title>Triple vs. Double Therapy in naïves HIV-Infected Patients</brief_title>
  <acronym>TRIDUNA</acronym>
  <official_title>Effectiveness of a Dual Therapy (Dolutegravir + Lamivudine) on Reduction of the Viral Reservoir, Immune Recovery and Immune Activation Compared With a Triple Therapy (Dolutegravir + Tenofovir Alafenamide/Emtricitabine) in Treatment-naïve HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospitales Universitarios Virgen del Rocío</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospitales Universitarios Virgen del Rocío</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to clarify whether if starting antiretroviral treatment based&#xD;
      on dual therapy (DTG + 3TC) could provide less control of residual HIV replication and,&#xD;
      therefore, a detriment on immune activation and inflammation compared to starting with triple&#xD;
      therapy, and could worsen the patients' long-term prognosis. For this purpose, the&#xD;
      investigator has designed a randomized clinical trial where will assess the immunological&#xD;
      recovery (CD4+/CD8+), immune activation, proliferation, senescence and apoptosis in T&#xD;
      lymphocytes CD4+ and CD8+ cells by flow cytometry, the immune activation of monocytes/&#xD;
      macrophages and plasma concentrations of various inflammatory mediators by ELISAS, and the&#xD;
      thymic function, the cellular reservoir of HIV and the degree of HIV DNA transcription by&#xD;
      digital dropped PCR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proviral HIV-DNA</measure>
    <time_frame>48 and 96 weeks</time_frame>
    <description>Mean changes in proviral HIV-DNA in PBMCs after 48 and 96 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune Recovery</measure>
    <time_frame>48 and 96 weeks</time_frame>
    <description>Mean changes immune recovery assessed by CD4+/CD8+ T cell ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Activation</measure>
    <time_frame>48 and 96 weeks</time_frame>
    <description>Mean changes immune activation assessed by the expression of HLA-DR and CD38 in both of CD4+ and CD8+ T cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytes Activation</measure>
    <time_frame>48 and 96 weeks</time_frame>
    <description>Mean changes monocytes activation (plasma sCD14 and sCD163).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunosenescense</measure>
    <time_frame>48 and 96 weeks</time_frame>
    <description>Mean changes expression of markers for recent thymic emigrants (CD31), proliferation (Ki67), dysfunction (PD-1), senescence (CD57), and apoptosis (annexin A) in both CD4+ and CD8+ T cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>48 and 96 weeks</time_frame>
    <description>Mean changes concentration of pro-inflammatory soluble mediator in plasma: TNF-α, IL-1β, IL-6, IP-10, IFN- γ, MIP-1α, MIP-1β, hsPCR y D-dímers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Reservoir</measure>
    <time_frame>48 and 96 weeks</time_frame>
    <description>Mean changes viral reservoir size, evaluated by proviral HIV-DNA and HIV-RNA in peripheral blood mononuclear cells (PBMC) and CD4+ T cells isolate.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Semen</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean changes of HIV-RNA seminal plasma viral load</description>
  </other_outcome>
  <other_outcome>
    <measure>GALT</measure>
    <time_frame>48 weeks</time_frame>
    <description>Mean changes of viral reservoir assessed as proviral HIV-DNA and HIV-RNA in GALT</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Dual Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dolutegravir plus lamivudine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dolutegravir plus TAF/FTC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Randomize</intervention_name>
    <description>Randomize to naive-treatment HIV-infected patients to receive dual o triple therapy as initial antiretroviral treatment</description>
    <arm_group_label>Dual Therapy</arm_group_label>
    <arm_group_label>Triple Therapy</arm_group_label>
    <other_name>Triple therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treatment-naïve HIV-1-infected patients ≥ 18 years of age.&#xD;
&#xD;
          -  Plasma HIV-1 RNA &gt;5000 and &lt;500.000 copies/ml.&#xD;
&#xD;
          -  T lymphocyte CD4+ count in peripheral blood &gt;200/μl.&#xD;
&#xD;
          -  Patients of childbearing age should consent to use a highly effective contraceptive&#xD;
             method from 15 days before the time of inclusion of the study until 30 days after the&#xD;
             end of it. It is considered a highly effective method:&#xD;
&#xD;
               -  Complete abstinence from penile-vaginal intercourse from 2 weeks prior to&#xD;
                  administration of Investigational Product, throughout the study, and for at least&#xD;
                  2 weeks after discontinuation of all study medications;&#xD;
&#xD;
               -  Any intrauterine device with published data showing that the expected failure&#xD;
                  rate is &lt;1% per year (not all intrauterine devices meet this criterion)&#xD;
&#xD;
               -  Male partner sterilization confirmed prior to the female subject's entry into the&#xD;
                  study, and this male is the sole partner for that subject.&#xD;
&#xD;
               -  Approved hormonal contraception.&#xD;
&#xD;
               -  Any other method with published data showing that the expected failure rate is&#xD;
                  &lt;1% per year.&#xD;
&#xD;
          -  Signed written informed consent prior to inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute HIV infection&#xD;
&#xD;
          -  T lymphocyte CD4+ count in peripheral blood ≤ 200/µl&#xD;
&#xD;
          -  Active opportunistic infection.&#xD;
&#xD;
          -  Pregnancy at inclusion or during the follow-up&#xD;
&#xD;
          -  Active hepatitis C and/or B virus co-infection.&#xD;
&#xD;
          -  ALT ≥ 5 times the ULN, or ALT ≥ 3xULN and bilirubin ≥ 1.5xULN (with &gt;35% direct&#xD;
             bilirubin).&#xD;
&#xD;
          -  Unstable liver disease (as defined by the presence of ascites, encephalopathy,&#xD;
             coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice),&#xD;
             cirrhosis, known biliary abnormalities (apart from hyperbilirubinemia or jaundice due&#xD;
             to Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  Subjects with severe hepatic impairment (Class C) as determined by Child-Pugh&#xD;
             classification.&#xD;
&#xD;
          -  Current or past disease that requires the use subsidiary of treatment with&#xD;
             corticosteroids, immunomodulatory agents, interferon or chemotherapeutic agents.&#xD;
&#xD;
          -  Any laboratory abnormality grade 3 or 4 according to the U.S. Department of Health and&#xD;
             Human Services, National Institutes of Health, National Institute of Allergy and&#xD;
             Infectious Diseases, Division of AIDS (Annex 3)&#xD;
&#xD;
          -  Concomitant use of drugs with potential major interactions with the prescribed drugs&#xD;
             according to the respective full prescribing information.&#xD;
&#xD;
          -  Estimated creatinine clearance &lt;50ml/min.&#xD;
&#xD;
          -  History or presence of allergy to the study drugs or their components&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis F Lopez-Cortes, MD, PhD</last_name>
      <phone>34 - 955013096</phone>
      <email>lflopez@us.es</email>
    </contact>
    <investigator>
      <last_name>Luis F Lopez-Cortes, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alicia Gutierrez-Valencia, Pharm D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pompeyo Viciana, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosa Ruiz-Valderas, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan R Castillo-Ferrando, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospitales Universitarios Virgen del Rocío</investigator_affiliation>
    <investigator_full_name>Luis F. Lopez-Cortes</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

